P2RY2 and acute myeloid leukemia: It will also upregulate the purinergic receptor P2Ry2 in AML cells and thereby activate PI3K-AKT signaling; inhibition of this pathway has therefore potentiated the antileukemic effects of selinexor in experimental models [199].